Analysis of genetic and clinical factors associated with buprenorphine response


Mental Illness Research, Education and Clinical Center, Crescenz Veterans Affairs Medical Center, Philadelphia, PA 19104, United States
Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, United States
Department of Epidemiology, University of Kentucky College of Public Health, Lexington, KY 40536, United States
Center on Drug and Alcohol Research, Department of Behavioral Science, University of Kentucky College of Medicine, Lexington, KY 40536, United States
VA Connecticut Healthcare System, US Department of Veterans Affairs, West Haven, CT 06516, United States
Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK
Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States

ARTICLE INFO

Keywords:
Buprenorphine
Genome-wide association study
Genetics
Treatment response
Opioid use disorder
Treatment predictors

ABSTRACT

Background: Buprenorphine, approved for treating opioid use disorder (OUD), is not equally efficacious for all patients. Candidate gene studies have shown limited success in identifying genetic moderators of buprenorphine treatment response.

Methods: We studied 1616 European-ancestry individuals enrolled in the Million Veteran Program, of whom 1609 had an ICD-9/10 code consistent with OUD, a 180-day buprenorphine treatment exposure, and genome-wide genotype data. We conducted a genome-wide association study (GWAS) of buprenorphine treatment response [defined as having no opioid-positive urine drug screens (UDS) following the first prescription]. We also examined correlates of buprenorphine treatment response in multivariable analyses.

Results: Although no variants reached genome-wide significance, 6 loci were nominally significant ($p < 1 \times 10^{-5}$), four of which were located near previously characterized genes: rs756770 ($ADAMTSL2$), rs11782370 ($SLC25A37$), rs7205113 ($CRISPLD2$), and rs13169373 ($LINC01947$). A higher maximum daily buprenorphine dosage (aOR = 0.98; 95%CI: 0.97, 0.995), greater number of UDS (aOR = 0.97; 95%CI: 0.96, 0.99), and history of hepatitis C (HCV) infection (aOR = 0.71; 95%CI: 0.57, 0.88) were associated with a reduced odds of buprenorphine response. Older age (aOR: 1.01; 95%CI: 1.000, 1.02) was associated with increased odds of buprenorphine response.

Conclusions: This study had limited statistical power to detect genetic variants associated with a complex human phenotype like buprenorphine treatment response. Meta-analysis of multiple data sets is needed to ensure adequate statistical power for a GWAS of buprenorphine treatment response. The most robust phenotype predictor of buprenorphine treatment response was intravenous drug use, a proxy for which was HCV infection.

1. Introduction

Buprenorphine is one of three FDA-approved medications for treating opioid use disorder (OUD). Although treatment with buprenorphine is associated with substantial benefits, including decreased opioid overdose risk (Larochelle et al., 2018), a significant proportion of individuals do not achieve long-term abstinence and drop out of care (Mattick et al., 2014). Knowledge of the factors that predict return to opioid use would enable clinicians to identify at-risk patients prospectively and modify treatment (e.g., by prescribing a higher dosage) to increase the likelihood of successful treatment.

Demographic factors, including age, sex, race, and ethnicity, have

https://doi.org/10.1016/j.drugalcdep.2021.109013
Received 25 February 2021; Received in revised form 12 August 2021; Accepted 15 August 2021
Available online 28 August 2021
0376-8716/Published by Elsevier B.V.
been associated with OUD treatment outcomes (Subramaniam et al., 2011; Schuman-Olivier et al., 2014; Huhn et al., 2019; Hser et al., 2014). Unemployment and injection drug use, possible proxy measures for the presence of comorbid conditions or disease severity, have also been associated with a return to opioid use or dropping out of treatment (Stein et al., 2005; Potter et al., 2013; Dreifuss et al., 2013). Electronic health records (EHRs) provide a wealth of patient data that could be used to identify factors that influence treatment outcomes. For example, mood disorder diagnoses are common among individuals with OUD (Savant et al., 2013) and have been associated with buprenorphine adherence rates (Gerra et al., 2004; Litz and Leslie, 2017; Peckham et al., 2020). EHRs also capture comorbid substance use disorders directly or through laboratory test results (e.g., urine drug screens (UDS)) or related diagnosis codes (e.g., alcohol-related cirrhosis). An important clinical problem among patients in treatment for OUD is the high rate of multi-substance use (Jones and McCance-Katz, 2019) and among patients receiving buprenorphine the use of substances other than opioids increases the likelihood that they will return to opioid use (Ferris et al., 2014; Sullivan et al., 2010).

Genetic variation among patients can result in differences in medication effectiveness through pharmacokinetic and/or pharmacodynamic mechanisms. Despite growing support for a pharmacogenetic approach across a variety of medications (Hull et al., 2019), the literature on genetic moderators of OUD treatment effectiveness is limited (Meaden et al., 2020). Response to methadone among patients of European ancestry has been associated with single nucleotide variation in DRD2, ARRB2, ALDH5A1, MYOC, and GRM6, as well as haplotypes in BDNF and OPRM1 (de Cid et al., 2008; Fonseca et al., 2010, 2014; Crettol et al., 2008; Oneda et al., 2011; Crist et al., 2016). Buprenorphine effectiveness in patients has also been linked to a variable number of tandem repeats polymorphism (Gerra et al., 2014) in SLC6A3 and, in multiple studies, to OPRD1 polymorphisms. Two intronic OPRD1 single nucleotide polymorphisms (SNPs) predicted sublingual buprenorphine treatment response in European-American (EA) women (Clarke et al., 2014). A different intronic OPRD1 SNP (rs678849) predicted buprenorphine treatment response in African-Americans (AA) (Crist et al., 2013), a finding that was replicated in an independent cohort (Crist et al., 2019). In a third study, in which patients were treated with extended-release buprenorphine (Kranzler et al., 2021), rs678849 predicted efficacy in EAs, but not AAs. In summary, while these pharmacogenetic studies provide suggestive evidence that genetic variation could moderate OUD treatment response, they are based on candidate gene approaches in cohorts of at most a few hundred patients, limiting their statistical power and the generalizability of the findings.

Here we present the first genome-wide association study (GWAS) of buprenorphine response in 1616 EA Veterans treated for OUD and enrolled in the Million Veteran Program (MVP). Despite the modest sample size for GWAS, there is evidence that statistical power is enhanced in the study of treatment-relevant variants relative to disease-related ones (Maranville and Cox, 2016). Further, a GWAS of usual methadone dose in a sample smaller than the one here yielded a genome-wide significant finding (Smith et al., 2017). We also characterized the phenotype by examining the associations between measures of treatment outcome and EHR variables previously linked to OUD or OUD treatment effectiveness, including demographic measures and comorbid diagnoses.

2. Materials and methods

2.1. Participants

MVP is a large biobank created and maintained by the US Department of Veteran Affairs (VA) (Gaziano et al., 2016), which at the time of the study included EHR data on over 700,000 Veterans, a majority of whom also had linked genetic data. The main MVP study and the analyses described here were approved by the Central VA Institutional Review Board. All patients provided written informed consent to participate in MVP.

We included 1616 EA Veterans enrolled in MVP and who had 1) an ICD-9-10 code consistent with OUD between August 2003 and November 2018; and 2) at least 60 consecutive days of sublingual buprenorphine/naloxone treatment based on EHR prescription data, including, but not limited to, prescriptions for the brand name medications Suboxone, Zubsolv, and Bunavail or for generic buprenorphine/naloxone. The buprenorphine treatment window was defined as the time period from the start of the initial prescription to a) the first two-week period in which no buprenorphine was prescribed or b) 180 days, whichever was shorter. For patients who had multiple distinct periods of buprenorphine treatment, only the first treatment period was included in the analysis.

Treatment response was measured by UDS for full opioid agonists, including methadone, within the treatment window. An opioid-positive UDS was defined as one that tested positive for one or more opioid agonists. If a confirmatory test of an opioid-positive UDS returned negative results, the UDS was considered to be a false positive and was coded as opioid-negative for the purposes of treatment response. Treatment responders were defined as having no opioid-positive UDS. This definition of treatment response was chosen over other possible outcome measurements, including the percentage of UDS positive for opioid agonists and treatment duration, because the distributions of these other definitions were skewed and thus did not lend themselves to GWAS (Supplemental Fig. 1).

2.2. Phenotype characterization

Potential correlates of buprenorphine treatment response were selected a priori. We used age at the time of the first buprenorphine prescription. Data on buprenorphine maximum daily dosage and UDS were obtained for the first 180 days of treatment. Comorbid psychiatric disorders and infectious diseases were considered present if there was 1 inpatient or 2 outpatient ICD-9-10 codes for them in the EHR (Supplemental Tables 2 and 3).

2.3. Statistical analysis

Descriptive statistics included means with standard deviations and medians with interquartile ranges for continuous variables and frequencies with percentages for categorical variables. Bivariate associations between potential correlates and buprenorphine response were assessed through simple logistic regressions. Variables with a p-value < 0.1 in bivariate analysis were included in a multivariable logistic regression model. A C-statistic was used to assess goodness of fit of the multivariable model. Analyses were performed using SAS 9.2 (Cary, NC) and an alpha of 0.05 was used to denote statistical significance.

2.4. Genotyping and imputation

Genotyping was performed using a custom Affymetrix Axiom biobank array containing 723,305 SNPs. The array is enriched for markers of AA and Hispanic ancestry and common diseases of interest to the VA population (Gaziano et al., 2016).

Samples with >2.5% missing genotype calls or high heterozygosity and SNPs with high missingness or deviation from the expected allele frequency were removed (Hunter-Zinck et al., 2020). It is now standard practice to impute SNP genotype data, allowing prediction of un-genotyped variants to increase the number of variants available for association testing (Marchini and Howie, 2010). Genotypes were pre-phased using EAGLE v2 and imputed via Minimac4 software using the 1000 Genomes Project phase 3 v5 reference panel (Auton et al., 2015). The top 30 principal components (PCs) were computed using FlashPCA on a dataset that included all MVP participants and an additional 2504 individuals from 1000 Genomes Phase 3. Genetically inferred ancestry,
derived from the PCs, and self-reported race/ancestry were unified to assign individuals to ancestral groups (HARE) (Fang et al., 2019). Within-ancestry PCs were then computed for MVP individuals within each ancestral group for use as covariates.

2.5. Genome-wide association analysis

Following imputation, 318,725 EA individuals in MVP were identified based on the HARE definition. Population-specific imputation quality (INFO) score was calculated, and SNPs with imputation quality <0.3 were excluded. A total of 1609 individuals had complete genomic analyses of GWAS results were performed using MAGMA and FUMA, respectively (https://fuma.ctglab.nl/) (de Leeuw et al., 2015; Watanabe et al., 2017).

2.6. Data availability

Summary statistics from the GWAS are available through dbGaP at accession no. phs001672.v3.p 1.

3. Results

3.1. Genome-wide association study of buprenorphine response

As shown in Fig. 1, the GWAS yielded six loci that were nominally significantly associated with buprenorphine treatment response (p < 1 × 10^-5), defined as continuous abstinence during buprenorphine treatment (Table 1). Three of the variants were located near previously characterized protein-coding genes: rs756770 (ADAMTSL2), rs11782370 (SLC25A37), and rs7205113 (CRISPLD2). A fourth variant (rs13169373) was located within the long intergenic non-coding RNA LINC01947. Two additional intergenic loci were also identified: rs62368105 (chr5:43970054) and rs6973474 (chr7:96804). Regional association plots for all nominally significant loci are provided in Supplemental Fig. 2. No variants were genome-wide significant (p < 5 × 10^-8). Analysis with MAGMA did not identify any genes significantly associated with buprenorphine treatment response after correction for multiple testing at a False Discovery Rate (FDR) of 0.05 (data not shown). Results for genes previously associated with OUD treatment response are provided in Supplemental Table 1. Functional analysis of the genes associated with the nominally significant variants identified in the GWAS was performed with FUMA (GENE2FUNC). No significant enrichment was observed (data not shown).

3.2. Phenotypic characterisation of buprenorphine response

Based on unadjusted associations, age, sex, and diagnoses for HIV or comorbid psychiatric or substance use disorders were not associated with buprenorphine response (Table 2; all p > 0.05). In the multivariable analysis, a higher maximum daily dosage of buprenorphine (aOR = 0.98; 95% CI: 0.97, 0.995) and a greater number of UDS (aOR = 0.98; 95% CI: 0.96, 0.99) were associated with significantly reduced odds of buprenorphine treatment response. Veterans with a history of hepatitis C (HCV) had 29% reduced odds of buprenorphine response compared to those without HCV (aOR = 0.71; 95% CI: 0.57, 0.88). Older age was significantly associated with higher odds of buprenorphine treatment response (aOR = 1.01; 95% CI: 1.00, 1.02).

4. Discussion

Abstinence during buprenorphine treatment was nominally associated with six loci, including variants near SLC25A37, ADAMTSL2, CRISPLD2, and LINC01947. SLC25A37 encodes an iron transporter localized to the mitochondrial membrane and is upregulated in the nucleus accumbens of individuals addicted to heroin or cocaine (Albertson et al., 2004, 2006). The lead variant from this locus (rs11782370) is an expression quantitative trait locus (eQTL) for SLC25A37 in multiple tissues, as well as for ENTPD4, a gene that is ~55 kb upstream of the SNP (GTEx Consortium, 2015). Polymorphisms in SLC25A37 have also been linked to major depressive disorder (Hu et al., 2016; Peterson et al., 2018), which may be relevant to buprenorphine treatment (Ghabrash et al., 2020), though depression was not significantly associated with treatment response in the current sample. ADAMTSL2 encodes a secreted glycoprotein and was associated in the UK Biobank data set with heaviness of smoking, a common comorbid
disorder in OUD patients (Quach et al., 2020). Despite the lead variant in this locus (rs756770) being intronic, it is not associated with ADAMTS12 expression (GTEx Consortium, 2015). However, it is identified as an eQTL for the upstream gene REXO4 in whole blood (GTEx Consortium, 2015). Finally, CRISPLD2 encodes a secreted anti-inflammatory protein that has been implicated in obesity and weight loss and is a valuable alternative metric, because HCV seropositivity is well captured in the EHR and direct information on injection drug use is not. Intravenous drug administration has been linked to the use of opioids and other substances during OUD treatment (Potter et al., 2013; Ledgerwood et al., 2019; Cox et al., 2013). People who inject drugs have high

Table 1
Nominally significant lead genetic variants associated with buprenorphine treatment response.

<table>
<thead>
<tr>
<th>SNP ID</th>
<th>Chromosome:Position</th>
<th>Effect Allele</th>
<th>Nearest Gene</th>
<th>Odds Ratio</th>
<th>Standard Error</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs62368105</td>
<td>5:43970054</td>
<td>G</td>
<td>NNT/FGF10</td>
<td>1.9437</td>
<td>0.147647</td>
<td>6.76 × 10⁻⁴</td>
</tr>
<tr>
<td>rs13169373</td>
<td>5:166345088</td>
<td>T</td>
<td>LINC01947</td>
<td>1.4346</td>
<td>0.0818052</td>
<td>9.54 × 10⁻⁴</td>
</tr>
<tr>
<td>rs6973474</td>
<td>7:96804</td>
<td>T</td>
<td>FAM20C</td>
<td>1.4043</td>
<td>0.0762082</td>
<td>8.36 × 10⁻⁴</td>
</tr>
<tr>
<td>rs11782370</td>
<td>8:23370018</td>
<td>T</td>
<td>SLC25A37</td>
<td>1.4843</td>
<td>0.0878757</td>
<td>6.97 × 10⁻⁴</td>
</tr>
<tr>
<td>rs756770</td>
<td>9:136398858</td>
<td>A</td>
<td>ADAMTS12</td>
<td>1.8599</td>
<td>0.138925</td>
<td>7.93 × 10⁻⁴</td>
</tr>
<tr>
<td>rs7205113</td>
<td>16:84487823</td>
<td>T</td>
<td>CRISPLD2</td>
<td>1.6486</td>
<td>0.112005</td>
<td>8.05 × 10⁻⁴</td>
</tr>
</tbody>
</table>

Table 2
Characteristics of the sample and associations with buprenorphine response (n = 1616).

<table>
<thead>
<tr>
<th></th>
<th>% (n)</th>
<th>Treatment response (n = 988)</th>
<th>Treatment non-response (n = 628)</th>
<th>Unadjusted OR (95 % CI)</th>
<th>P</th>
<th>Adjusted OR (95 % CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>92 % (1485)</td>
<td>92 % (908)</td>
<td>92 % (577)</td>
<td>1.00 (0.70, 1.45)</td>
<td>0.99</td>
<td>–</td>
<td></td>
</tr>
<tr>
<td>Age – Median (IQR)</td>
<td>45 (13.57)</td>
<td>46 (15.54)</td>
<td>45 (13.61)</td>
<td>1.01 (1.00, 1.02)</td>
<td>0.06</td>
<td>1.01 (1.00, 1.02)</td>
<td>0.04</td>
</tr>
<tr>
<td>% Opioid-positive UDS – mean (SD)</td>
<td>10 % (18.29 %)</td>
<td>–</td>
<td>25 % (21.87 %)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>% Opioid-positive UDS – Median (IQR)</td>
<td>12.50 % (628)</td>
<td>17 % (10 %, 33 %)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>% # of UDS – mean (SD)</td>
<td>11 (7.63)</td>
<td>10 (7.50)</td>
<td>12 (7.71)</td>
<td>0.97 (0.96, 0.98)</td>
<td>&lt;0.01</td>
<td>0.98 (0.96, 0.99)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>% # of UDS – Median (IQR)</td>
<td>9 (5, 14)</td>
<td>8 (4, 14)</td>
<td>10 (6, 15)</td>
<td>0.97 (0.96, 0.98)</td>
<td>&lt;0.01</td>
<td>0.98 (0.96, 0.99)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Max daily dosage of buprenorphine (mg) – mean (SD)</td>
<td>17 (7.29)</td>
<td>16 (7.46)</td>
<td>17 (7.96)</td>
<td>0.98 (0.96, 0.99)</td>
<td>&lt;0.01</td>
<td>0.98 (0.97, 0.995)</td>
<td>0.01</td>
</tr>
</tbody>
</table>

Treatmen response = no opioid-positive urine drug screen; Treatment non-response = at least 1 opioid-positive urine drug screen; UDS = urine drug screen; mg = milligrams; OR = odds ratio; SD = standard deviation; IQR = interquartile range; HCV = hepatitis C; PTSD = posttraumatic stress disorder; SUD = substance use disorder; OUD = opioid use disorder. Adjusted logistic regression c = 0.59.

GWAS of psychiatric disorders generally require samples in the tens of thousands to identify variants of genome-wide significance (Zhou et al., 2019; Zhu et al., 2020). Despite the lead variant in this locus (rs756770) being intronic, it is not associated with ADAMTS12 expression (GTEx Consortium, 2015). However, it is identified as an eQTL for the upstream gene REXO4 in whole blood (GTEx Consortium, 2015). Finally, CRISPLD2 encodes a secreted anti-inflammatory protein that has been implicated in obesity and weight loss and is a valuable alternative metric, because HCV seropositivity is well captured in the EHR and direct information on injection drug use is not.
rates of physical and psychiatric comorbidities and endorse a greater need for substance use treatment (Novak and Kral, 2011). Given the association between heroin use and intravenous drug administration, this finding may also reflect differences between people who use heroin and those who use prescription opioids (Jones, 2018). People who use heroin generally have worse buprenorphine treatment outcomes, including spending less time in treatment and having higher rates of opioid-positive UDS and of HCV infection than individuals who use only prescription opioids (Moore et al., 2007).

The VA is a large, nationwide medical system and standards for OUD treatment (e.g., inclusion criteria for buprenorphine treatment, dosage selection, frequency of UDS collection in buprenorphine-treated patients, methods of UDS testing) vary among VA facilities. This heterogeneity limited our ability to select potentially more informative phenotypes and identify genetic variants contributing to treatment response. The lack of specific information on drug use, including the route of administration and the type of opioids used (e.g., prescription vs. illicit) limited our ability to characterize the study sample phenotypically. The availability of this information would be useful in future work. Factors associated with buprenorphine response in the VA may not be generalizable to other healthcare systems, although future studies can evaluate the reliability of this phenotype in other settings. Additionally, it was a predominantly male sample and the analysis was limited to EA patients because of the much smaller number of buprenorphine-treated patients of other ancestries. Whereas our ability to generalize our findings to other population groups is limited, future studies should aim to expand the number of women and non-European-ancestry individuals. Further, greater uniformity in the VA approach to monitoring drug use among buprenorphine-treated patients would reduce variability in phenotyping for pharmacogenetic studies and also likely improve patient care.

In conclusion, we present the first GWAS of buprenorphine treatment response, together with the phenotype characterization of treatment outcomes. Our genetic findings include variants in several addiction-related genes that may be associated with buprenorphine treatment response, though they did not meet genome-wide statistical significance. We also found that HCV infection was correlated with buprenorphine non-response, supporting previously observed associations between measures of injection drug use and OUD treatment outcomes. We hope that this study provides an impetus for the collection of diverse cohorts of OUD patients being treated with buprenorphine, so as to permit the conduct of a multi-ancestry meta-GWAS of treatment response. Such a collaborative approach is likely to be the only way to ensure adequate statistical power to identify variants contributing to buprenorphine treatment response and to ensure the generalizability of the findings across population groups and both sexes.

Role of funding source

None.

Contributors

HRK, RCC, RVS, and RLK were responsible for the study concept and the design of the study. RCC, RVS, RLK, and CTR performed the phenotyping. RVS and RLK performed the data analysis. RCC, RVS, RLK, EEH, and HRK drafted the manuscript. CTR, EJE, and KMK provided critical revision of the manuscript. All authors approved the final version of the manuscript.

Declaration of Competing Interest

Dr. Kranzler is a member of an advisory board for Dicerna Pharmaceuticals; a consultant to Soprophyne Pharmaceuticals and Sobrera Pharmaceuticals; a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last three years by AbbVie, Alkermes, Dicerna, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, Pfizer, Arbor, and Amygdala Neurosciences; and is named as an inventor on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed January 24, 2018. Dr. Kampman has done work or served on advisory boards for Indivior Pharmaceuticals, World Meds, Alkermes, and Braeburn Pharmaceuticals.

Acknowledgements

This research is based on data from the Million Veteran Program (MVP), Office of Research and Development, Veterans Health Administration, and was supported by award #101 CX001734-01 (MVP012); the Veterans Integrated Service Network 4 Mental Illness Research, Education and Clinical Center; and P30 DA046345 from the National Institute on Drug Abuse. This publication does not represent the views of the Department of Veteran Affairs or the United States Government.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.drugalcdep.2021.109013.

References


